Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Dragonfly Energy

NASDAQ:DFLI

Stock Price:

$0.79 (-$0.02)

P/E Ratio:

-1.46

Market Cap:

$47.86 million

Average Trading Volume:

712,408 shares

Consensus Rating:

Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.79 (126.3% Upside)

Dragonfly Energy Holdings Corp. engages in the manufacturing and sale of deep cycle lithium-ion batteries for recreational vehicles, marine vessels, solar and off-grid residence industries, and industrial and energy storage markets. The company provides lithium power systems comprising solar panels, chargers and inverters, system monitoring, alternator regulators, accessories, and others. It also offers battery management systems for monitoring and controlling of battery systems and to protect battery cells from damage in various scenarios. The company provides its products under the Dragonfly Energy, Battle Born, and Wakespeed brand names. Dragonfly Energy Holdings Corp. is headquartered in Reno, Nevada.

#2 - Vor Biopharma

NYSE:VOR

Stock Price:

$0.91

P/E Ratio:

-0.51

Market Cap:

$61.98 million

Average Trading Volume:

496,396 shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$12.50 (1,279.5% Upside)

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

#3 - Aptose Biosciences

NASDAQ:APTO

Stock Price:

$0.74

P/E Ratio:

-0.12

Market Cap:

$13.39 million

Average Trading Volume:

77,009 shares

Consensus Rating:

Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$14.83 (1,905.6% Upside)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

#4 - Ovid Therapeutics

NASDAQ:OVID

Stock Price:

$0.84 (+$0.09)

P/E Ratio:

-1.14

Market Cap:

$59.29 million

Average Trading Volume:

516,983 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.70 (462.3% Upside)

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

#5 - Oatly Group

NASDAQ:OTLY

Stock Price:

$0.98 (+$0.03)

P/E Ratio:

-1.23

Market Cap:

$584.17 million

Average Trading Volume:

1.76 million shares

Consensus Rating:

Moderate Buy (5 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$2.11 (115.4% Upside)

Oatly Group AB, an oatmilk company, provides a range of plant-based dairy products made from oats in Europe, the Middle East, Africa, the Americas, and Asia. It offers Barista edition oatmilk, oatgurts, frozen desserts, ice-creams, and yogurts; cooking products, including cooking cream, in regular and organic, Crème Fraiche, whipping cream, vanilla custard, and spreads in a variety of flavors; and ready-to-go drinks. The company was formerly known as Havre Global AB and changed its name to Oatly Group AB in March 2021. Oatly Group AB was founded in 1994 and is headquartered in Malmö, Sweden.

#6 - Karyopharm Therapeutics

NASDAQ:KPTI

Stock Price:

$0.79 (-$0.03)

P/E Ratio:

-0.62

Market Cap:

$102.02 million

Average Trading Volume:

1.59 million shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.60 (482.2% Upside)

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

#7 - Sangamo Therapeutics

NASDAQ:SGMO

Stock Price:

$0.32

P/E Ratio:

-0.17

Market Cap:

$66.07 million

Average Trading Volume:

2.27 million shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.67 (1,679.7% Upside)

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

#8 - Lion Electric

NYSE:LEV

Stock Price:

$0.87 (+$0.01)

P/E Ratio:

-1.78

Market Cap:

$196.78 million

Average Trading Volume:

505,998 shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.74 (99.7% Upside)

The Lion Electric Company designs, develops, manufactures, and distributes purpose-built all-electric medium and heavy-duty urban vehicles in North America. The company's products include battery systems, chassis, bus bodies, and truck cabins. It distributes truck and bus parts, as well as accessories. The company was incorporated in 2008 and is based in Saint-Jérôme, Canada.

#9 - ESS Tech

NYSE:GWH

Stock Price:

$0.83 (+$0.03)

P/E Ratio:

-1.84

Market Cap:

$139.46 million

Average Trading Volume:

1.27 million shares

Consensus Rating:

Moderate Buy (2 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$2.11 (155.3% Upside)

ESS Tech, Inc., an energy storage company, designs and produces iron flow batteries for commercial and utility-scale energy storage applications worldwide. It offers energy storage products, which include Energy Warehouse, a behind-the-meter solution; and Energy Center, a front-of-the-meter solution. The company was founded in 2011 and is headquartered in Wilsonville, Oregon.

#10 - FTC Solar

NASDAQ:FTCI

Stock Price:

$0.32

P/E Ratio:

-0.82

Market Cap:

$40.20 million

Average Trading Volume:

707,702 shares

Consensus Rating:

Hold (2 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.49 (366.1% Upside)

FTC Solar, Inc. engages in the provision of solar tracker systems, software, and engineering services in the United States, Asia, Europe, the Middle East, North Africa, South Africa, and Australia. The company offers a self-powered, two-panel in-portrait, and single-axis tracker solution under the Voyager brand name; and a one module-in-portrait solar tracker solution under the Pioneer brand name. Its customers include project developers and solar asset owners, as well as engineering, procurement, and construction contractors that design and build solar energy projects. The company was incorporated in 2017 and is headquartered in Austin, Texas.

#11 - Chicken Soup for the Soul Entertainment

NASDAQ:CSSE

Stock Price:

$0.11 (-$0.01)

P/E Ratio:

-0.01

Market Cap:

$3.43 million

Average Trading Volume:

3.05 million shares

Consensus Rating:

Hold (2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.00 (3,691.5% Upside)

Chicken Soup for the Soul Entertainment, Inc. operates as an advertising-supported video-on-demand (VOD) company in the United States and internationally. It owns and operates various ad-supported and subscription-based VOD networks, including Redbox, Crackle, Chicken Soup for the Soul, Popcornflix, Popcornflix Kids, Popcornflix Comedy, FrightPix, Truli, and Españolflix, as well as Pivotshare, subscription VOD platform. The company also operates Redbox Free Live TV, a free ad-supported streaming television (FAST) service with various channels as well as a transactional video-on-demand (TVOD) service; and a network of kiosks for DVD rentals. In addition, it is involved in the creation, acquisition, and distribution of films and TV series; and licensing of content through theatrical, home video, pay-per-view, free, cable and pay television, and subscription and advertising video-on-demand platforms. The company was founded in 1993 and is headquartered in Cos Cob, Connecticut. Chicken Soup for the Soul Entertainment, Inc. operates as a subsidiary of Chicken Soup for the Soul Productions, LLC.

#12 - Zevia PBC

NYSE:ZVIA

Stock Price:

$0.62 (-$0.02)

P/E Ratio:

-1.28

Market Cap:

$45.96 million

Average Trading Volume:

449,304 shares

Consensus Rating:

Hold (2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.21 (421.7% Upside)

Zevia PBC, a beverage company, develops, markets, sells, and distributes various carbonated beverages in the United States and Canada. It offers soda, energy drinks, organic tea, and kidz drinks. The company offers its products through a network of food, drug, warehouse club, mass, natural, convenience, and e-commerce channels, as well as grocery distributors and natural product stores and specialty outlets. It provides its products under the Zevia brand name. The company was founded in 2007 and is headquartered in Encino, California.

#13 - Energy Vault

NYSE:NRGV

Stock Price:

$0.99 (+$0.02)

P/E Ratio:

-1.65

Market Cap:

$147.36 million

Average Trading Volume:

796,215 shares

Consensus Rating:

Hold (4 Buy Ratings, 0 Hold Ratings, 2 Sell Ratings)

Consensus Price Target:

$2.65 (167.7% Upside)

Energy Vault Holdings, Inc. develops and sells energy storage solutions. The company offers B-Vault, an electrochemical battery energy storage systems for shorter-duration energy storage needs; G-Vault, a proprietary gravity energy storage solution, including EVx solution; and H-Vault, a hybrid energy storage systems including systems that integrate green hydrogen. Its software solutions includes Vault-OS, an energy management system the management of one or more diverse storage mediums; Vault-Bidder that utilizes machine learning algorithms to match node-specific data with real-time weather and asset performance information; and Vault-Manager which designs to safeguard asset management and to help blend developing technologies seamlessly into existing solutions. Energy Vault Holdings, Inc. is based in Westlake Village, California.

#14 - Spruce Biosciences

NASDAQ:SPRB

Stock Price:

$0.57

P/E Ratio:

-0.50

Market Cap:

$23.44 million

Average Trading Volume:

877,170 shares

Consensus Rating:

Hold (2 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.00 (777.7% Upside)

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

#15 - Galecto

NASDAQ:GLTO

Stock Price:

$0.51 (+$0.01)

P/E Ratio:

-0.45

Market Cap:

$13.77 million

Average Trading Volume:

200,120 shares

Consensus Rating:

Hold (1 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.33 (753.0% Upside)

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

#16 - Allakos

NASDAQ:ALLK

Stock Price:

$0.77 (+$0.03)

P/E Ratio:

-0.31

Market Cap:

$67.88 million

Average Trading Volume:

1.04 million shares

Consensus Rating:

Hold (2 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$1.83 (139.2% Upside)

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

#17 - bluebird bio

NASDAQ:BLUE

Stock Price:

$0.94 (+$0.01)

P/E Ratio:

-1.26

Market Cap:

$102.29 million

Average Trading Volume:

7.86 million shares

Consensus Rating:

Hold (3 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$5.46 (483.9% Upside)

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

#18 - Polestar Automotive Holding UK

NASDAQ:PSNY

Stock Price:

$0.89 (-$0.08)

Market Cap:

$1.91 billion

Average Trading Volume:

6.70 million shares

Consensus Rating:

Hold (2 Buy Ratings, 2 Hold Ratings, 2 Sell Ratings)

Consensus Price Target:

$3.31 (270.3% Upside)

Polestar Automotive Holding UK PLC manufactures and sells premium electric vehicles. The company was founded in 2017 and is headquartered in Gothenburg, Sweden.

#19 - Bolt Biotherapeutics

NASDAQ:BOLT

Stock Price:

$0.73 (+$0.01)

P/E Ratio:

-0.44

Market Cap:

$28.02 million

Average Trading Volume:

172,266 shares

Consensus Rating:

Hold (0 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.50 (376.3% Upside)

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

#20 - LivePerson

NASDAQ:LPSN

Stock Price:

$0.72 (+$0.08)

P/E Ratio:

-0.50

Market Cap:

$56.23 million

Average Trading Volume:

2.94 million shares

Consensus Rating:

Hold (1 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$1.38 (92.0% Upside)

LivePerson, Inc. engages in conversational artificial intelligence. It enables brands to leverage the Conversational Cloud's intelligence engine to connect with consumers through an integrated suite of mobile and online business messaging technologies. The company offers the Conversational Cloud, an enterprise-class digital customer conversation platform, which enables businesses and consumers to connect through conversational channels, such as voice, in-app, and mobile messaging. It also provides professional services; LivePerson's Conversational AI, including conversation builder, manager, and intelligence, and intent manager. In addition, it provides Voice AI, conversational intelligence and insights, and integration services. The company sells its products to Fortune 500 companies, Internet businesses, online merchants, automotive dealers, educational institution, public sector, and not-for-profit organizations. It operates in the United States, Canada, Latin America, South America, Europe, the Middle East, Africa, the United Kingdom, and the Asia-Pacific. LivePerson, Inc. was incorporated in 1995 and is headquartered in New York, New York.

#21 - Cara Therapeutics

NASDAQ:CARA

Stock Price:

$0.29

P/E Ratio:

-0.13

Market Cap:

$15.58 million

Average Trading Volume:

705,133 shares

Consensus Rating:

Hold (0 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.93 (1,280.1% Upside)

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

#22 - Lyra Therapeutics

NASDAQ:LYRA

Stock Price:

$0.27

P/E Ratio:

-0.22

Market Cap:

$16.41 million

Average Trading Volume:

2.02 million shares

Consensus Rating:

Hold (1 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$7.13 (2,546.7% Upside)

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

#23 - AlloVir

NASDAQ:ALVR

Stock Price:

$0.72 (+$0.02)

P/E Ratio:

-0.44

Market Cap:

$83.15 million

Average Trading Volume:

890,359 shares

Consensus Rating:

Reduce (1 Buy Ratings, 3 Hold Ratings, 2 Sell Ratings)

Consensus Price Target:

$18.50 (2,458.8% Upside)

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

#24 - Amarin

NASDAQ:AMRN

Stock Price:

$0.74

P/E Ratio:

-6.16

Market Cap:

$303.73 million

Average Trading Volume:

1.82 million shares

Consensus Rating:

Reduce (1 Buy Ratings, 1 Hold Ratings, 2 Sell Ratings)

Consensus Price Target:

$1.08 (46.5% Upside)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

#25 - Ginkgo Bioworks

NYSE:DNA

Stock Price:

$0.34 (+$0.01)

P/E Ratio:

-0.78

Market Cap:

$737.46 million

Average Trading Volume:

68.04 million shares

Consensus Rating:

Reduce (1 Buy Ratings, 2 Hold Ratings, 3 Sell Ratings)

Consensus Price Target:

$1.56 (354.9% Upside)

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Ideas from MarketBeat

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.